Gain Therapeutics (GANX) AI Stock Analysis

• Market Cap: $88.85M
• Dividend Yield: N/A
• Average Volume (3M): 1.80M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: N/A
• EPS Growth: 42.29%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 38,462,086
• 10 Day Avg. Volume: 1,041,313
• 30 Day Avg. Volume: 1,798,788
• PEG Ratio: 0.05
• Price to Book (P/B): 6.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.62
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $7.50
• Price Target Upside: 250.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.50 ▲(16.82% Upside)

The score is mainly held back by weak financial performance (minimal revenue, significant losses, and ongoing cash burn). Technicals also lean negative in the near term (below 20D/50D with subdued momentum). A positive offset is the encouraging Phase 1b update and stated runway through year-end 2026, but valuation is constrained by negative earnings and no indicated dividend.

Positive Factors

Demonstrated CNS target engagement

Robust CSF biomarker reductions show CNS target engagement and pharmacodynamic effect for GT-02287, materially de‑risking the program vs. preclinical-only assets. This evidence supports progression to longer trials and sustained R&D prioritization over the next 2–6 months and beyond.

Proprietary discovery platform

A computational platform focused on protein misfolding creates a durable competitive capability: it can accelerate candidate identification, enable multiple programs, and attract partnerships or licensing, improving long‑term pipeline scalability and lowering marginal discovery costs.

Low balance sheet leverage

Very low debt reduces refinancing and interest risks for an early‑stage biotech, preserving operational flexibility to pursue clinical milestones. This structural balance‑sheet strength helps sustain R&D execution through near‑term development catalysts without heavy interest burdens.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow indicates high funding dependence; absent commercial revenue, the company must access capital to progress trials. This structural cash‑burn profile creates dilution and execution risk over multiple funding rounds.

Eroding equity base

A shrinking shareholder equity base reflects accumulated losses and reduced capital cushion, lowering the firm's ability to absorb setbacks or fund expansion without dilutive financings. This weakens long‑term financial resilience and bargaining power with partners or creditors.

No commercial revenue / high binary clinical risk

As a development‑stage company with negligible revenue, future value hinges on clinical success of GT‑02287 and subsequent commercialization. This creates a binary, long‑lived risk: failure in trials or regulatory hurdles would materially impair prospects and require fresh capital or partnerships.

Gain Therapeutics Business Overview & Revenue Model

Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

How the Company Makes Money

Gain Therapeutics primarily makes money through partnerships, collaborations, and licensing agreements with larger pharmaceutical and biotechnology companies. These partnerships usually involve upfront payments, milestone payments based on the achievement of development or regulatory milestones, and royalties on future sales of products developed using Gain's technology. Additionally, the company may receive research grants and funding for specific projects aimed at discovering therapies for rare diseases.

Gain Therapeutics Financial Statement Overview

Summary

Gain Therapeutics is facing significant financial challenges. The lack of revenue growth and persistent losses hinder profitability. While the company maintains low leverage, declining equity and asset levels raise concerns about financial stability. The negative cash flow highlights liquidity issues, impacting the company's operational sustainability.

Income Statement

Gain Therapeutics has faced declining revenues over the years, with 2024 showing no revenue. The company has persistent negative net income and EBIT, indicating profitability challenges. Gross profit margins are negative when revenue is present, showing inefficiencies in operations.

Balance Sheet

The company maintains a relatively low level of debt with a debt-to-equity ratio of 0.03 for 2024, which is a positive aspect. However, the declining stockholders' equity and total assets indicate potential risks in financial stability. The equity ratio decreased significantly over the years, suggesting increased reliance on liabilities.

Cash Flow

Gain Therapeutics struggles with negative operating cash flow, though there is improvement in free cash flow due to reduced capital expenditures. The operating cash flow to net income ratio is unfavorable, showing issues in converting profits into cash. Free cash flow remains negative, reflecting ongoing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	55.18K	132.64K	133.93K	28.88K
Gross Profit	-4.99M	0.00	55.18K	-8.11M	-7.03M	28.88K
EBITDA	-17.40M	-20.27M	-22.17M	-17.76M	-13.82M	-3.47M
Net Income	-19.39M	-20.41M	-22.27M	-17.59M	-13.89M	-3.58M
Balance Sheet
Total Assets	10.97M	12.12M	18.61M	24.10M	38.99M	9.60M
Cash, Cash Equivalents and Short-Term Investments	8.81M	10.39M	16.79M	20.14M	36.88M	7.49M
Total Debt	180.94K	653.01K	1.03M	1.27M	1.61M	1.26M
Total Liabilities	5.06M	4.78M	6.03M	5.22M	4.17M	3.40M
Stockholders Equity	5.91M	7.34M	12.58M	18.88M	34.82M	6.20M
Cash Flow
Free Cash Flow	-17.30M	-18.90M	-18.88M	-14.81M	-12.46M	-3.26M
Operating Cash Flow	-17.30M	-18.87M	-18.87M	-14.69M	-12.37M	-3.24M
Investing Cash Flow	-43.45K	4.98M	10.22M	-14.77M	-94.21K	-20.83K
Financing Cash Flow	14.21M	13.01M	12.64M	-78.77K	41.77M	10.49M

Gain Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Negative. The current price of 2.14 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 2.95, and above the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 34.68 is Neutral, neither overbought nor oversold. The STOCH value of 8.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GANX.

Gain Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRLD	56 Neutral	$148.90M	-1.36	-103.99%	―	250.00%	15.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	46 Neutral	$88.85M	-3.35	-261.72%	―	―	42.29%
PMVP	46 Neutral	$62.79M	-0.74	-51.87%	―	―	-58.47%
ABVC	44 Neutral	$52.98M	-9.32	-40.32%	―	56.52%	75.22%
PSTV	43 Neutral	$76.30M	-0.26	―	―	-8.16%	22.44%

Gain Therapeutics Corporate Events

Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data

On December 18, 2025, Gain Therapeutics reported exploratory endpoint data from Part 1 of its Phase 1b clinical study of GT-02287 in people with Parkinson’s disease, showing that all participants with elevated cerebrospinal fluid glucosylsphingosine experienced large reductions toward levels seen in healthy individuals after 90 days of treatment. The 21-patient study saw 19 complete the three‑month dosing period and 15 opt into a nine‑month extension that is expected to conclude in September 2026, with GT‑02287 remaining generally well tolerated at projected therapeutic exposures and the data monitoring committee recommending continuation without changes; combined with Phase 1 data in healthy volunteers demonstrating favorable safety, central nervous system exposure and target engagement, and confirmation that its current capital should fund operations through the Phase 1b extension and year‑end 2026, the company has strengthened its clinical and financial footing in the competitive Parkinson’s drug development space.

The most recent analyst rating on (GANX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.

Gain Therapeutics Announces New Stock Offering Program

Gain Therapeutics, Inc., a company involved in the sale of common stock, announced on November 28, 2025, that it has filed a prospectus supplement with the SEC for an ‘at the market offering’ program. This program allows the company to offer and sell up to $35,530,980.56 of its common stock through Oppenheimer & Co. Inc. as the sales agent. As of the announcement, the company has already sold $14,469,019.44 worth of stock under the existing Equity Distribution Agreement. The legal opinion regarding the validity of this stock offering has been provided by Lowenstein Sandler LLP.

The most recent analyst rating on (GANX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.